Unlock the full power of your protein production
Phenotypeca’s proprietary QTL technology is a next-generation strain optimisation platform. It provides full genome optimisation by combining deep genomic screening with targeted breeding to deliver production strains that are robust, reliable, and tailored to your exact protein, process and market needs.
What is QTL?
QTL (Quantitative Trait Locus) optimisation lets evolution generate the optimum strains and then identifies the specific regions of the genome that have been improved for key production traits – like yield, protein folding, secretion, genetic stability or downstream processing convenience.
Instead of relying on single-chassis strain engineering, QTL technology targets multiple traits simultaneously and evolves strains over billions of progeny to optimise them in combination.
How it works
- Strain breeding: We draw from proprietry yeast strain libraries, containing globally sourced diversity to maximise genetic potential.
- Whole-genome screening: Strain libraries are screened at scale to identify top performers.
- Iteration: The best performers are analysed to select suitable parents and bred again. Each round of breeding pushes the strain closer to peak performance.
This multi-round breeding process delivers strains that consistently outperform traditional single-step engineering.
Why it’s different
- Multi-trait optimisation — most methods focus on one trait at a time. QTL optimises multiple traits in parallel.
- Whole-genome power — rather than modifying a single or a few genes, we let nature evolve the entire genome for what matters most.
- IP protected — our method and strains are covered by a comprehensive IP estate, including exclusive rights to QTL-based strain optimisation.
What you get
- Higher titres, faster timelines
- Reduced downstream processing
- Robust, scalable manufacturing strains
- Overcoming complex issues such as protein folding and other post-translational modifications
- Animal-free and antibiotic-free production strains by default
Ready to scale
QTL strains are already powering breakthrough biosimilars, commercially valuable peptides, and breakthrough biologics. Let’s explore how they can transform your project.
